Safety and efficacy of abemaciclib plus endocrine therapy (ET) in elderly patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+, HER2-) advanced breast cancer: An age-specific subgroup analysis of MONARCH 2 and 3 trials

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >Safety and efficacy of abemaciclib plus endocrine therapy (ET) in elderly patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+, HER2-) advanced breast cancer: An age-specific subgroup analysis of MONARCH 2 and 3 trials

【24h】

Safety and efficacy of abemaciclib plus endocrine therapy (ET) in elderly patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+, HER2-) advanced breast cancer: An age-specific subgroup analysis of MONARCH 2 and 3 trials

机译：Abemaciclib Plus内分泌治疗的安全性和疗效（et）在患者激素受体阳性/人体表皮生长因子受体2阴性（HR +，Her2-）晚期乳腺癌：君主2和3次试验的年龄特异性亚组分析

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共3页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词

相似文献

外文文献
中文文献
专利

1. Safety and efficacy of abemaciclib plus endocrine therapy (ET) in elderly patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+, HER2-) advanced breast cancer: An age-specific subgroup analysis of MONARCH 2 and 3 trials [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：Abemaciclib Plus内分泌治疗的安全性和疗效（et）在患者激素受体阳性/人体表皮生长因子受体2阴性（HR +，Her2-）晚期乳腺癌：君主2和3次试验的年龄特异性亚组分析
2. Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3 [J] . Hope S. Rugo, Jens Huober, José A. García-Sáenz, The oncologist . 2021,第3期

机译：激素受体阳性人体表皮生长因子受体2阴性晚期乳腺癌患者的厌氧相关不良事件管理：君主2和君主的安全分析
3. Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3 [J] . Hope S. Rugo, Jens Huober, José A. García-Sáenz, The oncologist . 2021,第1期

机译：激素受体阳性人体表皮生长因子受体2阴性晚期乳腺癌患者的厌氧相关不良事件管理：君主2和君主的安全分析
4. Identification of Human Epidermal Growth Factor Receptor 2 Antagonist In Silico for Breast Cancer Therapy, Derived from Indonesian Phytochemicals [C] . Tuti Ratnasari, Dono indarto, Raden Ajeng Sri Wulandari, International Conference on Biomedical Engineering . 2018

机译：人类表皮生长因子受体2拮抗剂在二氧化硅中用于印尼治疗的印尼植物化学成分的鉴定。
5. Treatment Interruption and Discontinuation of Hormone Therapy in Hormone Receptor-Positive Breast Cancer Patients [D] . Mao, Daqin . 2020

机译：激素受体阳性乳腺癌患者中的治疗中断与激素治疗中的中断和停止
6. Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis [O] . Jiani Zheng, Jingxun Wu, Chunyue Wang, 2020

机译：细胞周期蛋白依赖性激酶4/6抑制剂与内分泌疗法与内分泌单一疗法联合治疗激素受体阳性人表皮生长因子受体2阴性的晚期乳腺癌的系统评价和荟萃分析
7. PCN160 COST-EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE COMPARED TO PALBOCICLIB PLUS LETROZOLE IN THE FIRST-LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED OR METASTATIC BREAST CANCER (ABC): A BRAZILIAN PRIVATE PAYER PERSPECTIVE [O] . A. Buehler, H.S.J. Kim, L. Fahham, 2019

机译：PCN160 Ribociclib的成本效果加上Letrozole与Palbociclib加仑唑唑加上患有激素受体阳性/人表皮生长因子受体2阴性（HR + / HER2-）先进或转移性乳腺癌（ABC）的前代妇女：巴西私人付款人的角度

Safety and efficacy of abemaciclib plus endocrine therapy (ET) in elderly patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+, HER2-) advanced breast cancer: An age-specific subgroup analysis of MONARCH 2 and 3 trials

著录项

相似文献

相关主题

期刊订阅